Adamas Pharmaceuticals Inc. (ADMS): Top insiders of ADMS Stock

H.C. Wainwright announced it was Reiterated coverage of Adamas Pharmaceuticals Inc. in a research note on December 18, 2019. The analysts assigned a Buy rating to the stock with a price target of $10. BofA/Merrill rated the stock as an Underperform in a research noted published on September 30, 2019. Cantor Fitzgerald rated the stock as a Neutral in a research note published on September 09, 2019.

Prentiss Christopher B, the Chief Financial Officer of Adamas Pharmaceuticals Inc., sold 1269.0 shares at the valuation of $5.92 during an exchange that occurred on Jan 21, which implies that Prentiss Christopher B is holding 70,940 shares at the estimation of $7,512 dependent on the most recent closing price.

In another transaction, on Sep 20, Chief Financial Officer of Adamas Pharmaceuticals Inc., MERRIWEATHER ALFRED G, sold 1584.0 shares at the price of $6.91. After this activity, MERRIWEATHER ALFRED G now keeps 48,019 shares of Adamas Pharmaceuticals Inc., esteemed at $10,945 with the most recent shutting price.

ADMS Recent Trade

The share price of ADMS ascended by $0.02 during the exchanging session on 07/14/20 to exchange at $2.65. Adamas Pharmaceuticals Inc. stock has an exchanging volume of 0.13 million shares, which is low, contrasted with its 3-months average volume of 458.37K shares. Its market capitalization has now reached to $70.15M.

ADMS Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, ADMS price has rose by 3.52%. In the course of past three months sees the stock go down around -19.21%, while it has lost -51.82% over the past six months and -30.08% since the start of the year.

ADMS Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Jun 2020), the firm recorded a revenue of 14.48 billion, which was higher than the gauge of 15.46M made by certain experts. For that equivalent quarter, Adamas Pharmaceuticals Inc. posted -$0.59 earnings per share (EPS) which was above the consensus estimate of -$0.77 by $0.18, which represents to an expansion by 23.40%.

ADMS Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Adamas Pharmaceuticals Inc. has seen its stock exchanging -27.99% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +9.05% above its three-month low. A more extensive look sees ADMS exchanging -65.94% beneath its 52-week high and 39.47% above from its 52-week low price.

ADMS Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 5.82%, while it has a month to month instability of 6.61%. The Company has an ATR (Average True Range) of 0.19 and a beta factor of 1.81.

Leave a Comment